Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsTherapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant PatientsTacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis.A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic riskAfrican-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipientsConsiderations in sirolimus use in the early and late post-transplant periods.The role of Thymoglobulin induction in kidney transplantation: an update.mTOR inhibitors and renal allograft: Yin and Yang.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation.Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
P2860
Q24246340-975E522E-8B91-4734-9C22-C82D549DCC30Q33432698-93A1F233-DD0B-4461-8019-E7CD4F084006Q34756444-33480C82-0440-4FDD-9C2A-BE29A1E02BC0Q35649082-CD03BBDD-72DF-4D7F-A632-43A08B59E0C8Q35946398-0D088B67-7FCA-4F94-9631-10ABD95A12E2Q37517602-59D48555-E285-44F7-8BF8-89BF312914E1Q38051718-7EA7F3C9-59BF-416C-9477-E8864E36CD45Q38209973-84DE1D5D-0144-43EA-AE63-38F1ED1493D2Q38668601-F56FEA5D-0A3F-4E1F-85BE-3E568FC300D2Q38779769-391E98EC-F251-4562-BBFE-4EC08FC0E24EQ39024541-6511C0B1-9224-4CDF-97D0-C55CFB8DDAB3Q43485988-3912BBE6-8349-495F-A422-7293DF7015C5Q51766509-DA658FDE-5BE1-497D-A172-03AB29999073
P2860
Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Observations regarding the use ...... daveric renal transplantation.
@en
Observations regarding the use ...... daveric renal transplantation.
@nl
type
label
Observations regarding the use ...... daveric renal transplantation.
@en
Observations regarding the use ...... daveric renal transplantation.
@nl
prefLabel
Observations regarding the use ...... daveric renal transplantation.
@en
Observations regarding the use ...... daveric renal transplantation.
@nl
P2093
P2860
P1476
Observations regarding the use ...... daveric renal transplantation.
@en
P2093
A Osama Gaber
Jonathan S Fisher
Lillian W Gaber
M Hosein Shokouh-Amiri
Maria Francesca Egidi
Nosratollah Nazakatgoo
P2860
P356
10.1111/J.1399-0012.2004.00116.X
P577
2004-02-01T00:00:00Z